Skip to content
TrialScanner

NCT04723537

Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease

Phase 2/Phase 3TerminatedRDHLLead

Registry record

Lead sponsor
RedHill Biopharma Limited
Conditions
Covid19
Primary completion
Dec 28, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04723537 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.